Injecto Polymers IPO Analysis & Review

Quick Answers

What is the Injecto Polymers IPO GMP today? The Injecto Polymers IPO GMP is ₹0 as of 11/9/2026, 3:05:11 am. The IPO price band is ₹100 - ₹100. GMP represents an unofficial grey-market indication and does not guarantee the listing price.

When does Injecto Polymers IPO open? The Injecto Polymers IPO opens on 2026-09-11 and closes on 2026-09-16.

What is the Injecto Polymers IPO subscription status? The overall subscription is 0x.

Key IPO Information

ViewIPO AI Analysis Score

The Injecto Polymers IPO scored 60/100 (Moderate Risk) in our deep analysis.

Frequently Asked Questions

What is the issue size of Injecto Polymers IPO?

The issue size is ₹56.12 crore, comprising a fresh issue of shares.

What is the price band for the Injecto Polymers IPO?

The price band is set at ₹98 to ₹100 per share.

What are the main products manufactured by Injecto Polymers?

The company manufactures polypropylene (PP) woven fabrics and bags, biaxially oriented polypropylene (BoPP) bags, leno bags, low-density and polyester pouches, flexible intermediate bulk container (FIBC) bags, and non-woven bags.

How will the IPO proceeds be utilized?

The net proceeds will be used for repayment/pre-payment of outstanding borrowings (₹10 crore) and funding capital expenditure for setting up phase IV at the existing manufacturing facility (₹30.50 crore), with the balance for general corporate purposes.

What are the key risks associated with the Injecto Polymers IPO?

Key risks include high customer concentration (top 10 customers contributed ~37% of FY26 revenue), reliance on trading activities, geographic concentration in West Bengal and eastern states, supplier concentration, negative operating cash flows, significant debt, and ongoing legal proceedings.

What is the company's revenue trend over the past three years?

Revenue increased from ₹109.05 crore in FY24 to ₹261.48 crore in FY25 and further to ₹375.53 crore in FY26, reflecting strong growth.

What is the company's customer concentration risk?

Revenue from the top 10 customers accounted for 40.07% in FY24, 40.63% in FY25, and 37.20% in FY26, indicating a significant reliance on a limited customer base.

What is the tentative listing date for the IPO?

The tentative listing date has not been explicitly disclosed in the prospectus; however, funds are expected to be unblocked on 21 September 2026, with listing likely thereafter.

View IPO
View IPO
Home›India›Injecto Polymers ()
Injecto Polymers Logo

Injecto PolymersBSE SME:

Analyzed by ViewIPO Financial Research Team
Plastic PackagingIndiaFiled 2026-09-11Listing 2026-09-21Size ₹56.44Cr
Lot Size 1200
Live GMP
(0%)
Check Allotment
Status Link

Is Injecto Polymers IPO Good? Quick Verdict

Injecto Polymers IPO scored 60/100 (Moderate Risk) in our deep analysis. The strongest pillar is Financial at 75/100, while Valuation is the primary concern at 50/100. Injecto Polymers IPO offers strong revenue growth and profitability improvements but is hampered by high customer and supplier concentration, negative operating cash flows, and significant debt, resulting in a mixed investment outlook.

IPO Score
60/100
Moderate Risk

Quick Verdict

Revenue grew from ₹109.05 Cr in FY24 to ₹375.53 Cr in FY26, demonstrating strong top-line expansion.
Profit after tax increased from ₹4.44 Cr to ₹16.01 Cr over the same period, indicating improving profitability.
ISO 9001:2015 and ISO 22000:2018 certifications ensure quality and food safety standards.
Revenue concentration with top 10 customers accounted for 37.2% of FY26 revenue, posing customer concentration risk.
Trading activities contributed 27.65% of FY26 revenue, exposing the company to commodity price volatility.
Negative operating cash flows of ₹48.80 Cr in FY26 indicate cash burn and liquidity pressure.

Company Snapshot

Revenue (TTM)
₹375.53Cr↑ 43.62% YoY
Profitability
PositiveNet Income ₹16.01Cr
Gross Margin
— 
Market Cap
—Pending Data
IPO Size
₹56.44Cr 
Industry
Plastic Packaging 
P/E Ratio
—Pending Data

Risk Breakdown

Governance
60
Moderate
Financial
75
Moderate
Valuation
50
Expensive
Competition
50
Expensive
Dilution
70
Moderate
Promoter / Mgmt
60
Moderate

AI Summary

Injecto Polymers Limited is a West Bengal-based manufacturer of plastic packaging products, including PP woven bags, BOPP bags, and FIBC bags, serving diverse industries such as agriculture, construction, and consumer goods. The company has demonstrated robust financial performance, with revenue rising from ₹109.05 crore in FY24 to ₹375.53 crore in FY26 and profit after tax increasing from ₹4.44 crore to ₹16.01 crore over the same period. However, the business faces notable challenges, including reliance on a limited number of customers and suppliers, geographic concentration in eastern India, and negative operating cash flows that raise liquidity concerns. The IPO proceeds of ₹56.12 crore are earmarked for debt repayment and capacity expansion, which could alleviate some of these pressures if executed successfully.

Overall Verdict: Injecto Polymers IPO offers strong revenue growth and profitability improvements but is hampered by high customer and supplier concentration, negative operating cash flows, and significant debt, resulting in a mixed investment outlook.

Key Highlights

  • •Manufacturer of PP woven fabrics, BOPP bags, leno bags, FIBC bags, and non-woven bags serving agriculture, construction, textiles, chemicals, and consumer goods.
  • •Two manufacturing units in West Bengal with in-house testing facility and 1 MWp rooftop solar power plant.
  • •ISO 9001:2015 (quality management) and ISO 22000:2018 (food safety) certified; BIS certification for food-grade packaging.
  • •Revenue increased from ₹109.05 Cr in FY24 to ₹375.53 Cr in FY26; PAT rose from ₹4.44 Cr to ₹16.01 Cr.
  • •Fresh issue IPO proceeds of ₹56.12 Cr to be used for debt repayment (₹10 Cr) and capex for phase IV expansion (₹30.50 Cr).
  • •Customer base diversified across industries but top 10 customers contributed ~37% of FY26 revenue.
  • •Ongoing capacity expansion: additional 2,400 MT under commissioning at Unit I and proposed 4,800 MT expansion.

Financial Performance

Revenue (Annual)

↑ +43.6% YoY

INR in Crores

Net Income (Annual)

↑ +97.4% YoY

INR in Crores

Cash Flow vs Profit

↓ -188.9% YoY

INR in Crores

CF
NP

EBITDA vs PAT

EBITDA YoY

INR in Crores

EBITDA
PAT

IPO Timeline

IPO Opens2026-09-11
IPO Closes2026-09-16
Basis of Allotment2026-09-17
Refunds & Demat2026-09-18
Listing Date2026-09-21

Valuation Analysis

IPO Price₹100
Estimated Fair Value
Pending Data
Valuation Premium
Pending
vs Fair Value

IPO DNA

Growth
62
Governance
60
Profitability
75
Valuation
50
Competition
50
Execution
60

Pros vs Cons

Pros

  • Revenue grew from ₹109.05 Cr in FY24 to ₹375.53 Cr in FY26, demonstrating strong top-line expansion.
  • Profit after tax increased from ₹4.44 Cr to ₹16.01 Cr over the same period, indicating improving profitability.
  • ISO 9001:2015 and ISO 22000:2018 certifications ensure quality and food safety standards.
  • In-house testing facility and 1 MWp rooftop solar plant support operational efficiency and sustainability.
  • Capacity expansions have increased installed capacity to 8,470 MT with further 2,400 MT under commissioning.

Cons

  • Revenue concentration with top 10 customers accounted for 37.2% of FY26 revenue, posing customer concentration risk.
  • Trading activities contributed 27.65% of FY26 revenue, exposing the company to commodity price volatility.
  • Geographic concentration: 85.27% of FY26 revenue from West Bengal, making the company vulnerable to regional disruptions.
  • Supplier concentration: top 10 suppliers accounted for 72.72% of FY26 purchases, creating supply chain risk.
  • Negative operating cash flows of ₹48.80 Cr in FY26 indicate cash burn and liquidity pressure.
  • Outstanding borrowings of ₹165.19 Cr represent significant leverage.
  • Ongoing legal proceedings involving promoters and directors could affect reputation and finances.

Financial Health

Revenue Growth
Revenue grew from ₹109.05 Cr in FY24 to ₹375.53 Cr in FY26, representing a CAGR of approximately 86% over two years. (Excellent)
Debt Level
Outstanding borrowings of ₹165.19 Cr as of FY26. (Moderate)
Cash & Equivalents
Cash and equivalents not disclosed in the prospectus. (Moderate)

Institutional Signals

Anchor Investors
Undisclosed
VC Backing Tier
Undisclosed
Strategic Partners
Undisclosed

Injecto Polymers IPO Reddit Pulse & Sentiment

Real-time Reddit discussions & retail sentiment

No Public Data Available

We couldn't find any significant public discussions or retail sentiment threads for this IPO at the moment.

Disclaimer: These are raw community discussions aggregated from public forums. The AI summary and Reddit comments do not constitute financial advice. Always conduct your own independent research.

Injecto Polymers IPO — Frequently Asked Questions

Related IPO Reports

Sonaselection

Sonaselection

SONAS
0/100
View Report
NSE

NSE

TEMPNSE1
60/100
View Report
Hero Motors

Hero Motors

HEROMOTORS
0/100
View Report
Jindal Supreme

Jindal Supreme

JINDAL
0/100
View Report
View All Active & Upcoming IPOs View IPO Calendar

IPO Terminology Explained

Confused by terms like GMP, Kostak, or Subject to Sauda? Read our detailed guides in the IPO Glossary to understand the terminology before you invest.

Grey Market Premium (GMP)Subject to SaudaASBAOffer for Sale (OFS)
View Full Glossary

Source Citation: All financial data and risk metrics are derived from the official prospectus filed with the regulator (SEBI DRHP/RHP). ViewIPO algorithms process this public data for informational purposes. Not financial advice.

Want to analyze another IPO?

Search any stock, IPO, company, ticker or filing and get instant AI-powered analysis.

Frequently Asked Questions about Injecto Polymers

What is the expected listing price of Injecto Polymers?

The expected listing price depends on the live Grey Market Premium. Check the live GMP and expected listing price for Injecto Polymers on our Live GMP Tracker.